Last updated: March 1, 2026
What Is NDC 24478-0074?
NDC 24478-0074 refers to a specific medication listed in the National Drug Code (NDC) system. Based on available data, this code corresponds to Zirabev (bevacizumab-bvzr) injection, a biosimilar marketed by Celltrion Healthcare. Zirabev is a biosimilar of Avastin (bevacizumab) used in oncology for metastatic colorectal cancer, non-small cell lung cancer, and other indications involving angiogenesis inhibition.
Market Landscape
Key Stakeholders
- Manufacturers: Celltrion Healthcare (Zirabev), Genentech/Roche (Avastin)
- Regulatory agencies: FDA, EMA
- Patients: Oncology patients requiring anti-VEGF therapy
- Providers: Oncology clinics, hospitals
Market Size and Demand
- U.S. Oncology Market: The bevacizumab market was valued at approximately $2.8 billion during 2021 (MarketResearch.com).
- Biosimilar Penetration: Biosimilars gained approval in the U.S. starting in 2017, gradually expanding share. Zirabev was approved by the FDA in February 2019.
- Projected Growth: Oncology biosimilars are expected to grow at a compounded annual growth rate (CAGR) of 13%, reaching $8 billion globally by 2027 (Frost & Sullivan).
Competitive Products
| Product |
Originator / Biosimilar |
Approval Year |
Market Dynamics |
| Avastin (bevacizumab) |
Originator |
2004 |
Dominates the market |
| Zirabev |
Biosimilar (Celltrion) |
2019 |
Growing market share |
| Mvasi (bevacizumab-awwb) |
Amgen |
2017 |
First biosimilar approved |
| BevaciExpr (hypothetical) |
Hypothetical biosimilar |
N/A |
Potential future entrant |
Market Penetration
- Zirabev holds approximately 10-15% of the U.S. bevacizumab market as of 2022.
- Biologics and biosimilars coexist, with biosimilar share expected to increase through price competition and physician acceptance.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): Zirabev's AWP is approximately 20-30% lower than Avastin's.
- Per-Vial Cost: Estimated at $250–$300 per 100-mg vial, versus Avastin at $350–$400.
Price Reduction Drivers
- Increased biosimilar competition.
- Negotiation leverage of hospitals and payers.
- Regulatory incentives and formulary preferences.
Future Price Projections (Next 3–5 years)
| Year |
Estimated Price per 100 mg vial |
Change from Baseline |
Key Drivers |
| 2023 |
$250–$280 |
Stable to slight decrease |
Market acceptance, supply chain stabilization |
| 2024 |
$240–$270 |
5–10% decrease |
Increased biosimilar competition, payer discounts |
| 2025 |
$220–$250 |
10–15% decrease |
Greater biosimilar penetration, cost-cutting |
| 2026 |
$210–$240 |
10% decrease |
Price compression continues |
These projections assume continued biosimilar uptake and price competition, with the potential for further declines if new biosimilars enter the market or if negotiated rebates increase.
Regulatory and Policy Factors
- Patent Expirations: The primary patents for Avastin expired in 2018–2019, opening the pathway for biosimilars.
- FDA Approvals: Biosimilar approvals, including Zirabev, adhere to FDA’s 351(k) pathway.
- Rebate and Pharmacy Benefit Manager (PBM) Negotiations: Rebate agreements significantly influence net prices.
Market Entry Barriers
- Physician Preference: Brand loyalty to Avastin persists despite biosimilar availability.
- Reimbursement Policies: CMS and private insurers influence prescribing patterns based on formulary placement.
- Manufacturing Capacity: Biosimilar production requires high-tech biomanufacturing facilities, limiting new entrants.
Key Takeaways
- Zirabev is experiencing increasing market share, with prices trending downward due to biosimilar competition.
- Prices are projected to decline by approximately 10-15% over the next three years.
- Market growth is driven by expanding indications, physician acceptance, and competitive pricing.
- Stakeholder negotiations, regulatory policies, and patent expirations shape pricing trajectories.
- Biosimilar penetration remains a key factor impacting long-term price stabilization.
FAQs
What is the primary use of NDC 24478-0074?
Zirabev is used in oncology to treat various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma, by inhibiting vascular endothelial growth factor (VEGF).
How does Zirabev compare price-wise to Avastin?
Zirabev's current wholesale price is estimated at roughly 20–30% less than Avastin, with ongoing price declines forecasted due to increased biosimilar competition.
What factors influence biosimilar market share?
Regulatory approval, physician and patient acceptance, formulary positioning, and reimbursement policies heavily influence biosimilar adoption.
What regulatory barriers could impact future pricing?
Patent litigations and patent expirations, coupled with the approval of additional biosimilars, influence market competition and pricing.
How might new biosimilar entrants affect prices?
Introduction of new biosimilars could accelerate price declines, especially if they offer better pricing, supply, or ease of use.
References
[1] MarketResearch.com (2022). Oncology Biosimilars Market Size & Trends.
[2] Frost & Sullivan (2022). Global Biosimilars Market Outlook.
[3] FDA (2019). FDA approves Zirabev (bevacizumab-bvzr) injection.
[4] IQVIA (2022). U.S. Oncology Market Trends.
